Phaseline

Targets › SLC9A3

SLC9A3 (Sodium/hydrogen exchanger 3): drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 3, 1 Phase 2; Neurology, Gastroenterology, Respiratory; next expected readout Feb 2027.

Plasma membrane Na(+)/H(+) antiporter. Exchanges intracellular H(+) ions for extracellular Na(+) in 1:1 stoichiometry, playing a key role in salt and fluid absorption and pH homeostasis (By similarity). (UniProt, P48764)

Open in Phaseline: the race on SLC9A3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ArdelyxTenapanor
Sodium/hydrogen exchanger 3 inhibitor
SLC9A3Phase 3Chronic Idiopathic Constipation (CIC); Cystic Fibrosis; SynucleinopathyFeb 2027

Conditions

Chronic Idiopathic Constipation (CIC) (1) Cystic Fibrosis (1) Synucleinopathy (1)

Modalities

small molecule (1)

Companies

Ardelyx (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.